Tilki D, Chen MH, Wu J, Huland H, Graefen M, Braccioforte M, Moran BJ, D’Amico AV. Surgery vs radiotherapy in the Management of biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. JAMA Oncol. 2018 Nov 15. doi: 10.1001/jamaoncol.2018.4836. [Epub ahead of print]

Agarwal M, Chhabra AM, Amin N, Braccioforte MH, Molitoris JK, Moran BJ. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer. Brachytherapy. 2018 Aug 21. pii: S1538-4721(18)30457-4.

King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D’Amico AV, Nguyen PL, Orio PF 3rd.brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 Apr;36(4):157.e15-157.e20.

Rose BS, Chen, MH, Wu J, BS, Braccioforte MH, Moran BJ, Doseretz DE, Katin MJ, Ross RH, Salenius SA, D’Amico AV.  Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer Specific Mortality Stratified by the Extent of Competing Mortality. Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(4):778-784.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Risk Group and Death From Prostate Cancer: Implications for active surveillance in Men With Favorable Intermediate-Risk Prostate Cancer. JAMA Oncol. 2015 Jun 1;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D’Amico AV. androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease. Cancer. 2015 Apr 29. doi: 10.1002/cncr.29420. [Epub ahead of print] 

Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, Frank SJ. Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):579-86. doi: 10.1016/j.ijrobp.2014.06.036. Epub 2014 Aug 20.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, D’Amico AV. Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e209-15.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D’Amico AV. neoadjuvant Hormonal Therapy Use and the Risk of Death in Men with Prostate Cancer Treated with brachytherapy Who Have No or at Least a Single Risk Factor for Coronary Artery Disease. Eur Urol. 2012 Sep 7. S0302-2838(12)01023-8.

Wattson DA, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Robertson CN, Polascik TJ, Braccioforte MH, Salenius SA, D’Amico AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e773-9.

Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D’Amico AV.
Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
Clin Genitourin Cancer. 2012 Mar;10(1):21-5.

Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D’Amico AV, Ennis RD. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1411-6.

Kang J, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D’Amico AV. Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e463-7.

Mitin T, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D’Amico AV. Diabetes mellitus, race and the odds of high grade prostate in men treated with radiation therapy. Journal of Urology, Dec 2011. Vol 186 No 6. p. 2233-2238.

Moran BJ, Derose P, Hsu IC, Abdel-Wahab M, Aterbery VE, Ciezki JP, Frank SJ, Mohler JL, Rosenthal SA, Rossi CJ Jr, Yamada Y, Merrick GS; Expert Panel on Radiation Oncology Oncology-Prostate:. ACR Appropriateness Criteria® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. American Journal of Clinical Oncology, Dec 2011. Vol 34 No 6. p. 636-647.

Hattangadi JA, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice. brachytherapy, Sep-Oct 2011. Vol 10 No 5. p. 369-375.

Expert Panel on Radiation Oncology-Prostate, Frank SJ, Aterbery VE, Hsu IC, Abdel-Wahab M, Ciezki JP, Hahn NM, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. Americal College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. brachytherapy, Sep-Oct 2011. Vol 10 No 5. p. 357-362.

Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Banez LL, Katin MJ, Braccioforte MH, D’Amico AV. Risk of death from prostate cancer after radical prostatectomy or brachytherpay in men with low or intermediated risk disease. Journal of Urology, July 2011. Vol 186 No 1. p. 91-96.

Ciezki JP, Hsu IC, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. American College of Radiology Approriateness Criteria (®) – Locally Advanced (High-risk) Prostate Cancer. Clinical Oncology, Aug 2011.

Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D’Amico AV. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. IJROBP, Apr 2011. Vol 79 No 5. p. 1318-1322.

Rossi CJ Jr, Joe Hsu IC, Abdel-Wahab M, Aterbery VE, Ciezki JP, Frank SJ, Hahn NM, Moran BJ, Rosenthal SA, Merrick G. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer. American Journal Clinical Oncology, Feb 2011. Vol 34 No 1. p. 92-98.

Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D’Amico AV. androgen suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int, Oct 2010. Vol 106 No 7. p. 979-985.

D’Amico AV, Braccioforte, MH, Moran BJ and Chen, MH. Causes of death in men with prevalent diabetes and newly diagnosed high-versus favorable-risk prostate cancer. IJROBP, Vol 77 (5). Pp. 1329-1337. 2010.

Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, D’Amico AV. Prostate cancer specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 116(11): 2590-5. Jun 2010.

Nanda, A., Chen, M.H., Moran, B.J., Braccioforte, M.H., Dosoretz, D., Salenius, S., Katin, M., Ross, R., and D’Amico, A.V. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therepy. International Journal of Radiation Oncology, Biology, Physics. May 2010. Vol 77 No 1. p. 147-152.

Pederson, AW, Moran BJ and Braccioforte MH. Single Institution Experience with Cesium-131 brachytherapy for Prostate Cancer. American Radium Society proceedings: 23, May, 2010.

Cheung AK, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin M, Ross R, D’Amico AV. The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American brachytherapy Society Guideline statement.
brachytherapy. 2010 Apr-Jun;9(2):145-50.

D’Amico, A.V., Braccioforte, M., Moran, B.S., and Chen, M.-H. (2009). Luteinizing-hormone Releasing hormone Therapy for Prostate Cancer and the Risk of Death from Alzheimer’s Disease. Alzheimer Disease & Associated Disorders – An International Journal. Jan-Mar 2010. Vol 24 No 1. p. 85-90.

Nanda, A., Chen, M.H., Braccioforte, M.H., Moran, B.J. and D’Amico, A.V. (2009). Hormonal Therapy Use for Prostate Cancer and Mortality in Men with Coronary Artery Disease-Induced Congestive Heart Failure or Myocardial Infarction. JAMA. Vol 302, No. 8, p. 866-873.

D’Amico, A.V., Moran, B.J., Braccioforte, M., Dosoretz, D., Selenius, S., Katin, M., Ross, R., and Chen, M.-H. Risk of death from prostate cancer after brachytherpay alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. Journal of Clinical Oncology. Aug 2009. Vol 27 No 24. p. 3923-3928.

Nanda, A., Chen, M.H., Moran, B.J., Braccioforte, M.H., Dosoretz, D., Salenius, S., Katin, M., Ross, R., and D’Amico, A.V. Total androgen Blockade versus a Luteinizing hormone-Releasing hormone Agonist Alone in Men with High-Risk Prostate Cancer Treated with Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics, Vol 77(1).p. 147-152. May 2010

Moran BJ and Braccioforte MH. Stereotactic Transperineal Prostate biopsy. Urology 73: 386-388, February, 2009.

Bice WS, Prestidge BR, Kurtzman SM, Beriwal S, Moran BJ, Patel RR and Rivard MJ. Recommendations for permanent prostate brachytherapy with Cs131: A consensus report from the Cesium Advisory Group. brachytherapy 7 (2008); p. 290-296.

Moran BJ, Braccioforte MH, Conterato DJ and Stutz MA. Cause-specific mortality in a large cohort of prostate cancer patients treated with brachytherapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5154)

Moran BJ and Braccioforte MH. Urinary morbidity Following Cs-131 brachytherapy for Localized Prostate Cancer. IJROBP, 1 November 2007 (Vol. 69, Issue 3, Page S378)

Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. IJROBP, Feb 2007. Vol 67 No 2. p.327-330.

Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M 3rd , Clark DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. brachytherapy. Jan-Mar 2007. Vol 6 No 1. p. 2-8.

Elshaikh MA, Kuban D, Levy L, Potters L, Blasko J, Beyer D, Zietman A, Moran BJ, Ciezki J and Zelefsky MJ. Long-term Multi-Institutional Outcome and biochemical Failure Definition Analysis of Combined Permanent brachytherapy With external beam radiation for Prostate Cancer. IJROBP, 1 November 2006 (Vol. 66, Issue 3, Pages S57-S58)

Moran BJ, Braccioforte MH and Conterato DJ. Re-biopsy of the Prostate Using a Stereotactic Transperineal Technique. Journal of Urology, Vol. 176, 1376-1381, October 2006.

Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. IJROBP, Vol 65 No 5. p. 1487-1493.

Moran BJ and Braccioforte MH. Permanent interstitial brachytherapy as a standalone treatment for Gleason 3+4 prostate cancer. brachytherapy, April-June 2006: Vol 5 No 2, p. 92.

Frank SJ, Blasko JC, Sylvester JE, Kuban DA, Moran BJ, Wallner KE, Vera R, Merrick GS, Zietman AL, Roach M, Clark D, Prestidge BR, Potters L, Michalski JM, Beyers DC, Lee WR, Stock RG, Davis BJ, Hurwitz MD, Grimm PD. interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States. brachytherapy, April-June 2006: Vol 5 No 2, p. 92.

Prestidge BR, Bice W, Jurkovic I, Moran BJ, Fuller D, Gray J, Beyer D, Kurtzman S, Sylvester J, Sadeghi A. A multi-institutional phase II trial for Cesium-131 permanent prostate brachytherapy. brachytherapy, April-June 2006: Vol 5 No 2, p. 92.

Moran BJ, Braccioforte MH, Stutz MA, Conterato DJ, Shafer J and Tanner A. Prostate size and the effect of hormonal manipulation. European Journal of Cancer 2005; Vol 3 No 2, p. 246.

Stutz MA, Braccioforte MH and Moran BJ. Prostate brachytherapy in morbidly obese patients. European Journal of Cancer 2005; Vol 3 No 2, p. 242.

Conterato DJ, Braccioforte MH and Moran BJ. Is Iodine allergy a contraindication to prostate brachytherapy using Iodine125? European Journal of Cancer 2005; Vol 3 No 2, p. 242.

Merrick GS, Butler WM, Wallner KE, Blasko, JC, Michalski J, Aronowitz J, Grimm P, Moran BJ, McLaughlin PW, Usher J, Lief JH, Allen ZA. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. brachytherapy 2005: Vol 4 No 4, p.241-251.

Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky T, Elshaikh M and Horwitz EM. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with permanent brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63: Issue 2 Supplement 1.

Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky M, Pisansky T, Elshaikh M and Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63: Issue 2 Supplement 1.

Moran BJ, Stutz MA, Gurel MH. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004; 59 (2) 392-396.

Lee PC, Parks EK, Moran, BJ. An innovative dosimetric model for formulating a semianalytical solution for the activity-volume relationship in prostate implants. Medical Dosimetry 2003; 28 (4) 243-253.

Stutz MA, Gurel MH, Moran BJ. Potency preservation after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 54: Issue 2 Supplement 0.

Moran BJ, Gurel MH, Visockis J, Geary P. Post-operative pain and prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 54: Issue 2 Supplement 0.

Stutz MA, Petrikas J, Raslowsky M, Lee PC, Gurel MH, Moran BJ. Seed loss through the urinary tract after prostate brachytherapy: examining the role of cystoscopy and urine straining post implant. Med Phys 2003; 30(10) 2695-2698.

Lee WR, Roach III M, Michalski J, Moran BJ, Beyer D. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002; 54 (2) p. 457-461.

Moran BJ, Conterato DJ, Stutz MA, Harris R, Raslowsky MP. Incidence of urinary incontinence after I125/Pd103 prostate brachytherapy in patients with prior TURP. Int J Radiat Oncol Biol Phys 2001; 51(3) Supplement 1, p. 324.

Moran BJ, Raslowsky MP, Visockis J, Stutz MA, Knight S, Kim W. General anesthesia for prostate brachytherapy using a laryngeal mask airway (LMA) and short acting anesthesia agents. Int J Radiat Oncol Biol Phys 2000; 48 (3) Supplement 1. p. 366

Stutz MA, Zuhlke K, Kraable D, Moran BJ. Comparing apples to apples: fusion of preplan ultrasound structures and postimplant CT images for prostate brachytherapy dosimetry. Int J Radiat Oncol Biol Phys 2001; 51: Issue 3 Supplement 1.

Moran BJ. Prostate brachytherapy in a free standing facility. American brachytherapy Society. 2001

Moran B, Raslowsky M, Stutz M. Prevention of perineal hematoma during prostate brachytherapy using the PPAD device. Radiological Society of North America, 2000.

Moran BJ, Janson KA, Raslowsky M, Stutz MA. The role of a needle manipulator/ruler in I125/Pd103 preloaded needle implants of the prostate. Radiological Society of North America, 2000.

Moran BJ, Janson K, Raslowsky MP. The role of TURP/TUIP for chronic urinary obstruction after 125I/103Pd prostate brachytherapy. Radiological Society of North America, 2000. Supplement.

Moran BJ, Raslowsky MP, Visockis J, Stutz MA, Knight S, Kim W. General anesthesia for prostate brachytherapy using a laryngeal mask airway (LMA) and short acting anesthetic agents. Int J Radiat Oncol Biol Phys 2000; 48: Issue 3 Supplement 1.

Moran BJ, Lee PC. 125 Gy or 135 Gy? Comments on the American brachytherapy Society article by Beter et al. Int J Radiat Oncol Biol Phys 2000; 47: 273-275.

Conterato DJ, Moran BJ, Janson KA, Hartsell W. The role of salvage prostate brachytherapy for patients failing external beam radiation therapy. RSNA 2000.

Moran BJ, Friedman JL, Grimm PD. Preplanned brachytherapy for prostate cancer. New Developments in Prostate Cancer Treatment Oncology Roundtable interviews 1999: 17-20.

Moran BJ. Multiple batch seed assay for I125/Pd103 used in prostate brachytherapy. Journal of Medical Physics, 1998.